NCT02649439View on ClinicalTrials.gov

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

March 28, 2019

Study Completion Date

October 1, 2022

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

PROSTVAC -V

Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus

BIOLOGICAL

PROSTVAC-F

Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus

Trial Locations (3)

10021

Memorial Sloan Kettering Cancer Center, New York

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02649439 - Prostvac in Patients With Biochemically Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter